Literature

ODN 2006 Vaccigrade

ODN 2006 is a synthetic oligodeoxynucleotide containing unmethylated CpG motifs (CpG ODNs). CpG ODNs are recognized by TLR9, which is expressed exclusively on human B cells and plasmocytoid dendritic cells (pDCs), thereby inducing Th1-dominated immune responses.

ODN 2006 VacciGrade™ is suitable for preclinical studies. It is prepared under strict aseptic conditions. It is guaranteed sterile and thoroughly tested for the presence of endotoxins.

ODN 2006 VacciGrade™ is for research use only, not for use in humans.

Specifications

Specificity: Th1 response

Working concentration: 20 - 50 μg/mouse

Solubility: 2 mg/ml in physiological water

ODN 2006 sequence: 5’-tcgtcgttttgtcgttttgtcgtt-3’ (24 mer)

Documents

• 1 mg of sterile lyophilized ODN 2006 VacciGrade™
• 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)

ODN 2006 VacciGrade™ is shipped at room temperature and should be stored at -20°C for up to 1 year. Upon resuspension, prepare aliquots of ODN 2006 VacciGrade™ and store at -20°C. Product is stable 6 months at -20°C when properly stored. Avoid repeated freeze-thaw cycles.

Description

Synthetic oligodeoxynucleotides containing unmethylated CpG motifs (CpG ODNs), such as ODN 2006, have been extensively studied as adjuvants [1]. These CpG motifs are present at a 20-fold greater frequency in bacterial DNA compared to mammalian DNA [2]. CpG ODNs are recognized by TLR9, which is expressed exclusively on human B cells and plasmacytoid dendritic cells (pDCs), thereby inducing Th1-dominated immune responses [3]. Pre-clinical studies, conducted in rodents and non-human primates, and human clinical trials have demonstrated that CpG ODNs can significantly improve vaccine-specific antibody responses [1].

Three types of stimulatory CpG ODNs have been identified, types A, B and C, which differ in their immune-stimulatory activities [4-5]. Furthermore, CpG ODNs activate TLR9 in a species-specific manner [6]. ODN 2006 is a type B CpG ODN specific for mouse TLR9. Type B CpG ODNs contain a full phosphorothioate backbone with one or more CpG dinucleotides and can strongly activate B cells [4]. ODN 2006 has been tested as an adjuvant in numerous animal models [7-9]. Research has demonstrated that ODN 2006 is an effective adjuvant for stimulating both antibody [8-9] and interferon-mediated cellular immune responses [9].

1. Steinhagen F. et al., 2011. TLR-based immune adjuvants. Vaccine 29(17):3341-55.
2. Hemmi H. et al., 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-5.
3. Coffman RL. et al., 2010. Vaccine adjuvants: Putting innate immunity to work. Immunity 33(4):492-503.
4. Krug A. et al., 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol, 31(7): 2154-63.
5. Marshall JD. et al., 2005. Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol. 24(2):63-72.
6. Bauer S. et al., 2001. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. PNAS, 98(16):9237-42.
7. Hartmann G. et al., 2000. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164(3): 1617 - 1624.
8. conforti VA. et al., 2007. The effectiveness of a CpG motif-based adjuvant (CpG ODN 2006) for LHRH immunization. Vaccine 25: 6537-43.
9. Zhang Y. et al., 2003. CpG ODN 2006 and IL-12 are comparable for priming Th1 lymphocyte and IgG responses in cattle immunized with a rickettsial outer membrane protein in alum. Vaccine 21:3307-18.

ORDERING